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Abstract
Background—Statins are cholesterol-lowering medications with pleiotropic effects including 
alterations in growth signaling as well as immunomodulatory and anti-inflammatory effects that 
may alter cancer risk. Evidence from previous epidemiologic studies is inconsistent regarding 
whether statin use is associated with reduced risk of pancreatic cancer (PC).
Methods—Patients with confirmed diagnoses of PC (cases) were recruited from medical and 
surgical oncology clinics, with controls (frequency-matched by sex and age) recruited from 
general medicine clinics, at a high-volume academic medical center over a six-year period (2006–
2011). Direct interviews were conducted using an epidemiological risk factor questionnaire 
covering topics such as medical history, lifestyle factors, and medication usage. Adjusted 
multivariable logistic regression was used to compute odds ratios (OR) and 95% confidence 
intervals (95%CI) as estimates of the relative risk of PC.
Results—Data were obtained from 536 cases and 869 controls. Ever use of statins was 
associated with 34% reduced PC risk (OR=0.66, 95%CI 0.47–0.92). In sex-stratified analyses, risk 
was statistically significantly reduced in men only (men: OR=0.50, 95%CI 0.32–0.79; women: 
OR=0.86, 95%CI 0.52–1.43). Duration of use was inversely associated with PC risk (>10 year 
use: OR=0.51 overall; in men, OR=0.41, 95%CI 0.21–0.80; ptrend=0.006).
Conclusions—This is the largest case-control study to demonstrate an inverse association 
between statin use and PC risk. Risk reduction in statin users appears to be sex-specific and is 
more pronounced in long-term users. Further research is warranted to better characterize this 
association and clarify roles of underlying biologic mechanisms.
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In 2014, pancreatic cancer (PC) represented the fourth-leading cause of cancer-related 
mortality among U.S. adults, with a projected 46,420 new cases and 39,590 deaths1. 
Approximately 75% of patients die within 1 year following diagnosis and 5-year survival is 
6%1. Only 15–20% of patients have potentially operable tumors at diagnosis; the majority 
present with incurable locally advanced or metastatic disease2. Population-based risk-
reduction strategies require improved understanding of factors that modulate risk, 
particularly modifiable factors. Known and suggested risk factors include male sex, 
increasing age, African-American ethnicity, smoking, obesity, type 2 diabetes (T2D), 
pancreatitis, and family history of PC3.
Statin medications, currently indicated for coronary heart disease and its risk equivalents4, 
lower serum cholesterol levels via competitive inhibition of HMG-CoA reductase (the rate 
limiting enzyme in cholesterol synthesis). Recently updated preventive health guidelines 
vastly expand the cohort of U.S. adults deemed likely to benefit from statins5. Due to their 
pleiotropic effects, they have been of considerable interest for cancer prevention and 
treatment. Data safety analyses of early randomized control trials (RCTs) of statins revealed 
an inverse association between statin use and cancer incidence6. Pre-clinical studies have 
demonstrated growth suppressive effects on various tumors, and epidemiologic studies have 
shown inverse associations with overall cancer risk7, 8 and risk of other gastrointestinal 
cancers including esophageal9, colorectal10, and liver11.
Previous studies of statin use and PC risk are inconsistent. Some RCTs and cohorts were 
underpowered12–17 and of non-trial studies7,18–26, few examined associations by sex with 
the exception of a large study of predominantly male veterans26 and a UK study19 where 
inverse relationships were observed only in men and male smokers, respectively.
To further examine the association between use of statin medications and PC risk among 
women and men combined and separately, we analyzed data collected in our large clinic-
based case-control study of PC in the San Francisco, California Bay Area. As anti-neoplastic 
effects may vary with drug characteristics27, 28, we also explored differential effects of 
statins individually and grouped by pharmacologic properties.
Methods
Study Population
Eligible patients diagnosed with exocrine pancreatic adenocarcinoma were recruited 
primarily from the University of California, San Francisco (UCSF) Gastrointestinal Medical 
and Surgical Oncology clinics (n=463), supplemented by recruitment from San Francisco’s 
California Pacific Medical Center (n=46) and the Cancer Prevention Institute of California’s 
early case ascertainment in Santa Clara and San Mateo counties (n=27). Eligible cases were 
U.S. residents 21–85 years old at diagnosis and able to complete a direct interview i.e. spoke 
English, no cognitive impairment. Diagnoses were confirmed by patients’ medical records, 
cancer registry and Surveillance Epidemiology and End Results abstracts that included 
histologic or cytologic confirmation of diagnoses. Controls were recruited from UCSF 
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General Medicine Primary Care clinics and were frequency-matched to cases by sex and age 
in 5-year groups. Eligibility criteria for controls were the same as for cases with the 
exception of PC diagnosis. All participants were enrolled from 2006–2011 and provided 
informed consent for interview and biospecimen collection. Cases provided additional 
consent for medical record access of data pertaining to their disease and follow-up telephone 
contact. The study was approved by the UCSF Committee on Human Research.
Data collection
Data were collected during direct interviews using a standard epidemiologic risk factor 
questionnaire where queries for most exposures were restricted to >1 year before diagnosis 
(cases) or interview (controls). No proxy interviews were conducted. Specific to these 
analyses, participants were asked whether they had ever been diagnosed with 
hypercholesterolemia, had ever taken prescription hypolipidemic medications for ≥4 days 
per week for ≥3 months and if so, their age at first use, last use, and total duration of use. 
Cue cards with brand and generic medication names helped facilitate recall.
Statistical analysis
Statistical analyses were conducted using SASv9.3 (SAS Institute, Inc., Cary, NC). 
Preliminary analyses were conducted using parametric and non-parametric statistics. Age at 
PC diagnosis (cases) or interview (controls) was grouped as ≤50, 51–60, 61–70, >70 years 
old. Body mass index (BMI) was computed as usual adult weight/height2 (kg/m2) and 
grouped per World Health Organization categories. Alcohol consumption was analyzed as 
average drinks/week over the past 10 years and cigarette smoking as never smoker, quit >15 
years ago, quit 1–15 years ago, quit <1 year ago/current smoker.
Hypolipidemic medication use was analyzed by drug class and grouped into mutually 
exclusive categories of use: never, non-statins, non-statins and statins, and statins only. 
Drug-specific analyses were limited to exclusive use of that medication. Never users of 
hypolipidemics constituted the referent group in all analyses.
Exploratory analyses of pharmacologic properties of specific statins included potency 
(recommended starting dose 20–40mg/day vs 10–20mg/day), derivation (biologic vs 
synthetic), bioavailability (≤5% vs ≥12%), solubility (lipophilic vs hydrophilic), phase I 
metabolism (CYP450 3A4 vs other), production of active metabolites (none/minor vs 
major), renal excretion (≤10% vs ≥13%), and half-life (<3 hours vs >11 hours)29. Users of 
multiple statins that crossed categories within a pharmacologic property were analyzed as 
“mixed” use.
Multivariable unconditional logistic regression was used to compute odds ratios (OR) with 
95% confidence intervals (95%CI) as estimates of relative risk. Models were adjusted for 
matching factors or for all potential confounders of PC (age, sex, race, BMI, alcohol, 
tobacco, hypercholesterolemia, diabetes, pancreatitis, family history of PC, and duration of 
statin use for statin subgroup analyses) and are hereto forward referred to as “adjusted” or 
“fully adjusted” respectively. Ever use of non-statin hypolipidemics did not change risk 
estimates >10% and therefore was not included in final models. Linear trend in odds ratios 
was based on the Wald chi-square statistic for the factor modeled as an ordinal variable. 
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Effect modification by sex was explored in stratified analyses. Demographic characteristics 
of non-UCSF cases were similar to UCSF cases and sensitivity analyses showed similar 
results for analyses of all cases and for UCSF cases only. Thus the total case population was 
used for all analyses. Data are not tabled for ≤5 exposed participants. All statistical tests 
were two-sided and considered statistically significant for p<0.05.
Results
Of potentially eligible cases aged 21–85 years, ~12% were ineligible due to language 
problems and ~3% were cognitively impaired, not located or dead, leaving 698 eligible PC 
cases. Of these, 16% refused, 6% were too ill and 2% expressed privacy concerns or 
participation in another study, for a final participation rate of 76%. Cases were recruited at a 
median of 61 days after PC diagnosis (interquartile range 25–148 days). Among controls, 
~34% of patients approached did not meet eligibility requirements e.g. language problems, 
incompatible age-group. Of eligible clinic controls, 35% had no time, 3% refused, 6% were 
too ill and 3% had privacy concerns, for a final participation rate of 53%. These analyses 
include the eligible 536 cases and 869 frequency-matched controls who completed 
interviews.
Compared with controls, cases were slightly older and a greater proportion were men, 
consumed alcohol, were overweight or obese, or had T2D or pancreatitis (Table 1). Nearly 
half of both cases and controls reported a history of hypercholesterolemia.
Hypolipidemics were ever used by 34.0% of cases and 36.9% of controls (Table 2). Statins 
were the most commonly used (32.6% cases, 35.7% controls) and 23.9% of statin users took 
two or more different statins. Both cases and controls with T2D were more likely to have 
hypercholesterolemia and use cholesterol-lowering drugs including statins. Of note, one-
third of the 39 statin users without hypercholesterolemia had T2D and 180 patients with 
hypercholesterolemia never used statins.
Ever use of statins was associated with a reduced PC risk (adjusted OR=0.66, 95%CI 0.47–
0.92, Table 3). Sex-stratified analyses showed this was mainly due to the association in men 
(men: adjusted OR=0.50, 95%CI 0.32–0.79; women: adjusted OR=0.86, 95%CI 0.52–1.43). 
In contrast, use of other hypolipidemics was not associated with PC risk regardless of 
exclusivity of use, although estimates were imprecise.
Duration of statin use was inversely associated with risk, particularly among long-term users 
(used >10 years: fully adjusted OR=0.51, 95%CI 0.31–0.85, ptrend=0.01, Table 3). Age at 
first use was not associated with PC risk in fully adjusted models and did not confound the 
association between PC risk and duration of use (Table 3). Median age at first use in men, 
57 years (interquartile range 50–64), was similar to that in women, 58 years (interquartile 
range 52–65) (data not tabled). In sex-stratified analyses, a trend of reduced risk with 
increased duration of use was statistically significant in men only (men, ptrend=0.006; 
women ptrend=0.44; Table 3).
Atorvastatin was the most common exclusively-used statin (Table 4). Only exclusive 
pravastatin use was associated with a statistically significant decreased PC risk (fully 
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adjusted OR=0.22, 95%CI 0.06–0.82) and the magnitude of the OR was similar for men and 
women, although imprecise. Use of multiple statins was associated with a 56% reduced PC 
risk, statistically significant in men only (OR=0.30, 95%CI 0.10–0.86). Among those who 
took multiple statins, 86.2% used atorvastatin and 72.4% used simvastatin.
Exploratory analyses of the pharmacologic characteristics of statins disclosed few 
associations with PC risk (Table 5) with the exception of drug bioavailability. Compared 
with exclusive use of statins with low bioavailability (≤5%), those who exclusively used 
high bioavailability (≥12%) statins had reduced risk of PC (p=0.01). However, this was 
observed in men only (men: p=0.01, women: p=0.26). Interestingly, participants in the 
“mixed” use group were at lowest risk and were the only group with statistically 
significantly decreased risk compared with non-users. Other pharmacologic characteristics 
were not associated with risk when compared with non-users or in comparisons of high and 
low intensity exposure. However, those in the “mixed” use groups for derivation, renal 
excretion, and elimination had statistically significantly reduced PC risk compared with non-
users.
Discussion
To our knowledge, this is the largest published case-control study to demonstrate an inverse 
association between statin use and PC risk, and to conduct detailed analyses by sex and 
pharmacologic properties. Associations were observed in men only. PC risk was inversely 
associated with duration of statin use and lowest in men long-term users regardless of age at 
first use. The decreased risk of PC with exclusive pravastatin use was novel to our study but 
requires confirmation and should be interpreted cautiously.
Statins are hypothesized to decrease cancer risk partly via the downstream effects of HMG-
CoA reductase inhibition in the mevalonate pathway. Specifically, inhibition disrupts 
synthesis of cholesterol and farnesyl or geranylgeranyl disphophates (FPP, GGPP) which 
function in prenylation of the G-proteins Rho and Ras, as well as other proteins involved in 
cell signaling6,30,31. Relevant to pancreatic cancer, aberrant Ras signaling is integral to 
pancreatic tumorigenesis32,33 whereas Rho mediates epidermal growth factor signaling and 
is implicated in other cancer-related mechanisms including angiogenesis34,35, tumor 
invasion and metastasis36,37, and activation of the NF-κB pathway38. Statins also might 
impact cancer development via other direct anti-inflammatory and immunomodulatory 
effects6,39. Interestingly, results from recent meta-analyses of RCT data show that statins 
may reduce risk of acute pancreatitis and increase diabetes risk40, conditions associated with 
increased PC risk. The association between statin use and cancer is complex, organ 
dependent and confounded by intermediary health conditions requiring carefully designed 
studies to better understand the mechanisms driving the observed pleiotropy.
Our findings of sex-specific associations expand on results from a large nested case-control 
study of predominantly male U.S. veterans that showed statistically significantly reduced PC 
risk in statin users (OR=0.33), particularly long-term users (>4 years; OR=0.20)26, as well 
as a recent UK case-control study that reported a reduced risk of PC with statin use among 
male smokers (OR=0.11)19. Other studies that reported null associations with PC 
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risk7,18,20,21,25 typically had matched on sex and had too few cases to conduct sex-stratified 
analyses. However, earlier results for all-cause mortality and stroke where decreased rates 
were observed in men only41,42 provide additional evidence of statins’ sex-specific effects. 
Integration of the accumulating data suggests sex-related effects of statins, including 
potential anti-neoplastic associations. Underlying mechanisms to explain these differences 
are uncertain and poorly understood. With few published studies among women, further 
research is warranted.
Our detailed analyses of pharmacologic properties of statins are unique to our study. Results 
were null from earlier analyses that assessed medication derivation or solubility43,44. Our 
observed inverse associations with bioavailability are intriguing but could be spurious given 
that the lowest PC risk was observed among those in the “mixed” group of users. Overall, 
our results do not suggest that specific pharmacologic characteristics might confer 
exceptionally low PC risk.
Strengths of this study include the large sample size, the short duration between case 
diagnosis and interview, and the experienced, well-trained interviewers who administered a 
structured questionnaire in-person to collect data about potential and known confounders, 
effect modifiers and risk factors of PC in a standard manner. Data about most exposures 
excluded the year before diagnosis/interview to diminish effects of reverse causation. 
Cancer registry and medical record data were used to confirm PC diagnoses. Study 
limitations include the potential for recall bias inherent in case-control studies although 
direct interviews and use of cue cards to facilitate recall helped to diminish exposure 
misclassification. A potential for selection bias among controls is possible as a high 
frequency of controls “had no time” or could only partially complete an interview during the 
clinic visit. Our use of clinic-based controls, which compared with population-based 
controls may include a greater prevalence of unhealthy persons, i.e. smokers, also may have 
influenced our findings although our controls were largely being seen for acute conditions or 
healthy annual exams. Also, UCSF is a tertiary care center and cancer patients are often 
referred for surgery or clinical trial consideration, options that generally necessitate good 
functional status. Compared with 2006–2011 San Francisco-Oakland SMSA SEER data45 
for pancreatic cancer patients, a greater proportion of study patients were non-Hispanic 
white (85% vs 61%), were younger at diagnosis (median age 63 vs 70 years), and had earlier 
stage disease at diagnosis (regional stage, 42% vs 34%; advanced stage 41% vs. 56%). Thus, 
our results may pertain to a healthier population of PC patients than in the broader 
community. Finally, statins have been previously associated with increased adherence to 
preventive health measures46, suggesting that statin use may be a surrogate for a healthier 
lifestyle or better functional status. This potential bias should be considered in the 
interpretation of our findings, although potential confounding due to lifestyle factors 
associated with increased risk of PC such as obesity, smoking and alcohol consumption was 
adjusted for in our analyses.
In conclusion, this represents the largest case-control study to demonstrate an inverse 
relationship between statin use and PC risk, particularly in men and in long-term users. 
Prospective clinical evaluation of statins as preventive therapy, e.g. in individuals at 
particularly high risk of PC, represents an intriguing possibility.
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Table 1
Sociodemographic characteristics of pancreatic cancer cases and controls, University of California San 
Francisco
Cases (%) n=536 Controls (%) n=869
Sex
 Men 284 (53.0) 420 (48.3)
 Women 252 (47.0) 449 (51.7)
Age
 ≤50 70 (13.0) 159 (18.3)
 51–60 142 (26.5) 299 (34.4)
 61–70 178 (33.2) 244 (28.1)
 >70 146 (27.2) 167 (19.2)
Race
 Non-Hispanic White 453 (84.5) 744 (85.6)
 Non-White 83 (15.5) 125 (14.4)
Body Mass Index
 ≤25 267 (49.8) 472 (54.3)
 25–30 205 (38.3) 265 (30.5)
 >30 64 (11.9) 132 (15.2)
Cigarette Smoking
 Never Smoker 262 (48.9) 425 (48.9)
 Quit >15 years ago 147 (27.4) 248 (28.5)
 Quit 1–15 years ago 57 (10.6) 91 (10.5)
 Current Smoker 70 (13.1) 105 (12.1)
Average Weekly Alcohol Use
 Non-drinker 190 (35.4) 347 (39.9)
 1–7 drinks/week 221 (41.2) 362 (41.7)
 8–14 drinks/week 71 (13.3) 67 (7.7)
 15–21 drinks/week 29 (5.4) 35 (4.0)
 >22 drinks/week 25 (4.7) 58 (6.7)
Pancreatitis1
 No 496 (92.7) 852 (98.0)
 Yes 39 (7.3) 17 (2.0)
Family History of Pancreatic Cancer
 No 507 (94.6) 835 (96.1)
 Yes 29 (5.4) 34 (3.9)
Type 2 Diabetes
 No 455 (84.9) 780 (89.8)
 Yes 81 (15.1) 89 (10.2)
Hypercholesterolemia1
 No 296 (55.2) 457 (52.7)
 Yes 240 (44.8) 411 (47.4)
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1
Unknown: N=1.
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Table 2
Non-exclusive ever use of hypolipidemic medications, University of California San Francisco case-control 
study of pancreatic cancer.
Hypolipidemic Medication1 Cases (n=536) Controls (n=869)
n (%) n (%)
Never 354 (66.0) 548 (63.1)
Ever 181 (34.0) 320 (36.9)
Any Statin 175 (32.6) 310 (35.7)
 Atorvastatin 97 (18.1) 213 (24.5)
 Fluvastatin 1 (0.2) 2 (0.2)
 Lovastatin 31 (5.8) 46 (5.3)
 Pravastatin 7 (1.3) 42 (4.8)
 Rosuvastatin 9 (1.7) 11 (1.3)
 Simvastatin 70 (13.1) 108 (12.4)
Bile Acid Sequestrants 3 (0.6) 3 (0.3)
Cholesterol Absorption Inhibitors 20 (3.7) 26 (3.0)
Fibrates 8 (1.5) 11 (1.3)
Nicotinic Acid 3 (0.6) 19 (2.2)
No. of Different Statin Medications
 0 360 (67.3) 558 (64.3)
 1 144 (26.9) 225 (25.9)
 2 26 (4.9) 62 (7.1)
 3–4 5 (0.9) 23 (2.7)
1
Unknown: N=2.
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